Share Price and Basic Stock Data
Last Updated: July 26, 2025, 2:05 pm
| PEG Ratio | 184.21 |
|---|
Quick Insight
Biogen Pharmachem Industries Ltd, currently priced at ₹0.93, holds a market capitalization of ₹83.9 crore, yet lacks critical financial metrics such as net profit, reserves, and borrowings, which raises concerns about transparency and operational stability. With a return on equity (ROE) and return on capital employed (ROCE) both at a mere 0.39%, the company's profitability and efficiency appear significantly constrained. The absence of institutional and promoter holdings, alongside a public ownership of 99.99% among 280,600 shareholders, suggests a highly fragmented share structure. Investors should exercise caution, as these factors indicate potential vulnerabilities in the company's financial health and governance.
Competitors of Biogen Pharmachem Industries Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| MKVentures Capital Ltd | 645 Cr. | 1,679 | 2,400/1,151 | 68.8 | 267 | 0.06 % | 16.5 % | 9.56 % | 10.0 |
| Modern Shares & Stockbrokers Ltd | 12.5 Cr. | 42.8 | 67.7/36.4 | 57.0 | 43.5 | 0.00 % | 3.32 % | 1.74 % | 10.0 |
| Monarch Networth Capital Ltd | 2,960 Cr. | 374 | 501/261 | 19.8 | 102 | 0.13 % | 33.3 % | 26.1 % | 10.0 |
| Monotype India Ltd | 47.8 Cr. | 0.68 | 2.42/0.65 | 4.65 | 0.02 | 0.00 % | 286 % | % | 1.00 |
| Multipurpose Trading & Agencies Ltd | 4.88 Cr. | 9.85 | 13.3/8.25 | 28.7 | 10.3 | 0.00 % | 4.44 % | 3.91 % | 10.0 |
| Industry Average | 6,902.51 Cr | 1,458.22 | 80.79 | 3,733.88 | 0.37% | 21.18% | 13.30% | 7.34 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -0.18 | -1.54 | 0.00 | 0.00 | -0.01 | 0.75 | 0.00 | 0.00 | 0.78 | -0.09 | 0.00 | 0.23 | 1.35 |
| Expenses | 0.06 | 0.05 | 0.11 | 0.03 | 0.19 | 0.34 | 0.04 | 0.03 | 0.04 | 0.07 | 0.35 | 0.54 | 0.17 |
| Operating Profit | -0.24 | -1.59 | -0.11 | -0.03 | -0.20 | 0.41 | -0.04 | -0.03 | 0.74 | -0.16 | -0.35 | -0.31 | 1.18 |
| OPM % | 54.67% | 94.87% | -134.78% | 87.41% | |||||||||
| Other Income | 0.01 | 0.00 | 2.05 | 0.33 | 0.00 | 0.00 | 0.76 | 0.09 | 0.00 | 0.00 | -0.65 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.23 | -1.59 | 1.94 | 0.30 | -0.20 | 0.41 | 0.72 | 0.06 | 0.74 | -0.16 | -1.00 | -0.31 | 1.18 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.23 | -1.59 | 1.94 | 0.30 | -0.20 | 0.41 | 0.72 | 0.06 | 0.74 | -0.16 | -1.00 | -0.31 | 1.18 |
| EPS in Rs | -0.00 | -0.02 | 0.03 | 0.00 | -0.00 | 0.01 | 0.01 | 0.00 | 0.01 | -0.00 | -0.02 | -0.00 | 0.02 |
Last Updated: May 31, 2025, 6:41 am
Below is a detailed analysis of the quarterly data for Biogen Pharmachem Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 1.35 Cr.. The value appears strong and on an upward trend. It has increased from 0.23 Cr. (Dec 2024) to 1.35 Cr., marking an increase of 1.12 Cr..
- For Expenses, as of Mar 2025, the value is 0.17 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.54 Cr. (Dec 2024) to 0.17 Cr., marking a decrease of 0.37 Cr..
- For Operating Profit, as of Mar 2025, the value is 1.18 Cr.. The value appears strong and on an upward trend. It has increased from -0.31 Cr. (Dec 2024) to 1.18 Cr., marking an increase of 1.49 Cr..
- For OPM %, as of Mar 2025, the value is 87.41%. The value appears strong and on an upward trend. It has increased from -134.78% (Dec 2024) to 87.41%, marking an increase of 222.19%.
- For Other Income, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Depreciation, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.18 Cr.. The value appears strong and on an upward trend. It has increased from -0.31 Cr. (Dec 2024) to 1.18 Cr., marking an increase of 1.49 Cr..
- For Tax %, as of Mar 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00%.
- For Net Profit, as of Mar 2025, the value is 1.18 Cr.. The value appears strong and on an upward trend. It has increased from -0.31 Cr. (Dec 2024) to 1.18 Cr., marking an increase of 1.49 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.02. The value appears strong and on an upward trend. It has increased from 0.00 (Dec 2024) to 0.02, marking an increase of 0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 2:30 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.95 | 0.00 | 1.62 | 2.47 | 0.00 | 0.79 | 0.84 |
| Expenses | 0.03 | 0.04 | 0.03 | 0.12 | 6.72 | 0.95 | 0.12 | 3.22 | 2.49 | 0.45 | 0.43 | 1.13 |
| Operating Profit | -0.03 | -0.04 | -0.03 | -0.12 | -6.61 | 0.00 | -0.12 | -1.60 | -0.02 | -0.45 | 0.36 | -0.29 |
| OPM % | -6,009.09% | 0.00% | -98.77% | -0.81% | 45.57% | -34.52% | ||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.01 | 0.91 | 1.59 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| Depreciation | 0.10 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.13 | -0.14 | -0.03 | -0.12 | -6.56 | 0.00 | -0.12 | -1.60 | -0.01 | 0.46 | 1.93 | -0.29 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Net Profit | -0.13 | -0.13 | -0.03 | -0.12 | -6.56 | 0.00 | -0.12 | -1.60 | -0.01 | 0.46 | 1.93 | -0.29 |
| EPS in Rs | -0.00 | -0.00 | -0.00 | -0.00 | -0.10 | 0.00 | -0.00 | -0.02 | -0.00 | 0.01 | 0.03 | -0.00 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 76.92% | -300.00% | -5366.67% | 100.00% | -1233.33% | 99.38% | 4700.00% | 319.57% | -115.03% |
| Change in YoY Net Profit Growth (%) | 0.00% | 76.92% | -376.92% | -5066.67% | 5466.67% | -1333.33% | 1332.71% | 4600.62% | -4380.43% | -434.59% |
Biogen Pharmachem Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -30% |
| TTM: | 352% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 30% |
| 3 Years: | 4% |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -1% |
| 3 Years: | 0% |
| Last Year: | 0% |
Last Updated: Unknown
Balance Sheet
Last Updated: July 25, 2025, 1:41 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 |
| Reserves | -4.14 | -4.27 | -4.30 | -4.42 | -10.98 | -10.99 | -9.51 | -11.12 | -11.13 | -10.67 | -8.74 | 26.67 |
| Borrowings | 57.21 | 10.00 | 6.21 | 0.72 | 0.01 | 0.63 | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 4.93 | 2.49 | 1.64 | 1.69 | 1.64 | 2.73 | 0.03 | 0.11 | 0.82 | 0.24 | 0.30 | 0.09 |
| Total Liabilities | 123.26 | 73.48 | 68.81 | 63.25 | 55.93 | 57.63 | 56.09 | 54.25 | 54.95 | 54.83 | 56.82 | 92.02 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 60.86 | 43.78 | 26.69 | 22.39 | 3.52 | 6.25 | 6.45 | 9.49 | 6.95 | 8.85 | 5.44 | 23.84 |
| Other Assets | 62.40 | 29.70 | 42.12 | 40.86 | 52.41 | 51.38 | 49.64 | 44.76 | 48.00 | 45.98 | 51.38 | 68.18 |
| Total Assets | 123.26 | 73.48 | 68.81 | 63.25 | 55.93 | 57.63 | 56.09 | 54.25 | 54.95 | 54.83 | 56.82 | 92.02 |
Below is a detailed analysis of the balance sheet data for Biogen Pharmachem Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 65.26 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 65.26 Cr..
- For Reserves, as of Mar 2025, the value is 26.67 Cr.. The value appears strong and on an upward trend. It has increased from -8.74 Cr. (Mar 2024) to 26.67 Cr., marking an increase of 35.41 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 0.09 Cr.. The value appears to be improving (decreasing). It has decreased from 0.30 Cr. (Mar 2024) to 0.09 Cr., marking a decrease of 0.21 Cr..
- For Total Liabilities, as of Mar 2025, the value is 92.02 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 56.82 Cr. (Mar 2024) to 92.02 Cr., marking an increase of 35.20 Cr..
- For Fixed Assets, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 23.84 Cr.. The value appears strong and on an upward trend. It has increased from 5.44 Cr. (Mar 2024) to 23.84 Cr., marking an increase of 18.40 Cr..
- For Other Assets, as of Mar 2025, the value is 68.18 Cr.. The value appears strong and on an upward trend. It has increased from 51.38 Cr. (Mar 2024) to 68.18 Cr., marking an increase of 16.80 Cr..
- For Total Assets, as of Mar 2025, the value is 92.02 Cr.. The value appears strong and on an upward trend. It has increased from 56.82 Cr. (Mar 2024) to 92.02 Cr., marking an increase of 35.20 Cr..
Notably, the Reserves (26.67 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -57.24 | -10.04 | -6.24 | -0.84 | -6.62 | -0.63 | -0.43 | -1.60 | -0.02 | -0.45 | 0.36 | -0.29 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 23,326.82 | 3,085.21 | 572.28 | 0.00 | 0.00 | |||||||
| Inventory Days | 0.00 | 0.00 | 0.00 | |||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 23,326.82 | 3,085.21 | 572.28 | 0.00 | 0.00 | |||||||
| Working Capital Days | 23,194.09 | 2,651.05 | 549.75 | 152.21 | -106.27 | |||||||
| ROCE % | -0.22% | -0.14% | -0.15% | -0.04% | -0.19% | -11.32% | 0.00% | -0.22% | -2.90% | -0.02% | -0.37% | 0.65% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.00 | 0.03 | 0.01 | 0.00 | -0.02 |
| Diluted EPS (Rs.) | 0.00 | 0.03 | 0.01 | 0.00 | -0.02 |
| Cash EPS (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.41 | 0.86 | 0.83 | 0.82 | 0.82 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.41 | 0.86 | 0.83 | 0.82 | 0.82 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 |
| PBDIT / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| PBIT / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| PBT / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| Net Profit / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| PBDIT Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| PBIT Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| PBT Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| Net Profit Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| Return on Networth / Equity (%) | -0.31 | 3.41 | 0.83 | -0.01 | -2.96 |
| Return on Capital Employeed (%) | -0.31 | 3.41 | 0.83 | -0.01 | -2.96 |
| Return On Assets (%) | -0.31 | 3.39 | 0.83 | -0.01 | -2.95 |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 0.00 | 0.04 | 0.02 |
| Current Ratio (X) | 29.51 | 0.30 | 0.64 | 2.37 | 23.64 |
| Quick Ratio (X) | 29.51 | 0.30 | 0.64 | 2.37 | 23.64 |
| Interest Coverage Ratio (X) | 0.00 | 0.00 | 0.00 | -46.77 | -34255.66 |
| Interest Coverage Ratio (Post Tax) (X) | 0.00 | 0.00 | 0.00 | -46.77 | -34255.66 |
| Enterprise Value (Cr.) | 60.63 | 69.16 | 38.37 | 91.28 | 13.70 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 36.89 | 8.44 |
| EV / EBITDA (X) | -207.15 | 35.82 | 84.25 | -10849.12 | -8.54 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 36.93 | 8.45 |
| Price / BV (X) | 0.68 | 1.22 | 0.70 | 1.69 | 0.25 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 36.94 | 8.47 |
| EarningsYield | 0.00 | 0.02 | 0.01 | 0.00 | -0.11 |
After reviewing the key financial ratios for Biogen Pharmachem Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.41. It has increased from 0.86 (Mar 24) to 1.41, marking an increase of 0.55.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.41. It has increased from 0.86 (Mar 24) to 1.41, marking an increase of 0.55.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is -0.31. This value is below the healthy minimum of 15. It has decreased from 3.41 (Mar 24) to -0.31, marking a decrease of 3.72.
- For Return on Capital Employeed (%), as of Mar 25, the value is -0.31. This value is below the healthy minimum of 10. It has decreased from 3.41 (Mar 24) to -0.31, marking a decrease of 3.72.
- For Return On Assets (%), as of Mar 25, the value is -0.31. This value is below the healthy minimum of 5. It has decreased from 3.39 (Mar 24) to -0.31, marking a decrease of 3.70.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Current Ratio (X), as of Mar 25, the value is 29.51. This value exceeds the healthy maximum of 3. It has increased from 0.30 (Mar 24) to 29.51, marking an increase of 29.21.
- For Quick Ratio (X), as of Mar 25, the value is 29.51. This value exceeds the healthy maximum of 2. It has increased from 0.30 (Mar 24) to 29.51, marking an increase of 29.21.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 60.63. It has decreased from 69.16 (Mar 24) to 60.63, marking a decrease of 8.53.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is -207.15. This value is below the healthy minimum of 5. It has decreased from 35.82 (Mar 24) to -207.15, marking a decrease of 242.97.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 1.22 (Mar 24) to 0.68, marking a decrease of 0.54.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Biogen Pharmachem Industries Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -0.31% (Industry Average ROCE: 21.18%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.31% (Industry Average ROE: 13.3%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 29.51
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 73.1 (Industry average Stock P/E: 80.79)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
Biogen Pharmachem Industries Ltd. is a Public Limited Listed company incorporated on 13/07/1995 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L51100GJ1995PLC026702 and registration number is 026702. Currently company belongs to the Industry of Finance & Investments. Company's Total Operating Revenue is Rs. 0.00 Cr. and Equity Capital is Rs. 65.26 Cr. for the Year ended 31/03/2025.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Finance & Investments | Shop No. 8, First Floor, Rajkot Gujarat 360001 | suntechnooverseas@gmail.com http://www.biogenpharma.life |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Niraj Vaghela | WholeTime Director & CFO |
| Mr. Chandrakant Govindbhai Parmar | Director |
| Mr. Chhayaben Parmar | Director |
| Mr. Narendrakumar Vaniya | Director |
| Mr. Komalben Chauhan | Director |
| Mr. Harshadkumar Rathod | Director |
FAQ
What is the intrinsic value of Biogen Pharmachem Industries Ltd?
Biogen Pharmachem Industries Ltd's intrinsic value (as of 27 July 2025) is 0.33 66.33% lower the current market price of 0.98, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 88.5 Cr. market cap, FY2025-2026 high/low of 1.54/0.75, reserves of 26.67 Cr, and liabilities of 92.02 Cr.
What is the Market Cap of Biogen Pharmachem Industries Ltd?
The Market Cap of Biogen Pharmachem Industries Ltd is 88.5 Cr..
What is the current Stock Price of Biogen Pharmachem Industries Ltd as on 27 July 2025?
The current stock price of Biogen Pharmachem Industries Ltd as on 27 July 2025 is 0.98.
What is the High / Low of Biogen Pharmachem Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Biogen Pharmachem Industries Ltd stocks is ₹1.54/0.75.
What is the Stock P/E of Biogen Pharmachem Industries Ltd?
The Stock P/E of Biogen Pharmachem Industries Ltd is 73.1.
What is the Book Value of Biogen Pharmachem Industries Ltd?
The Book Value of Biogen Pharmachem Industries Ltd is 1.41.
What is the Dividend Yield of Biogen Pharmachem Industries Ltd?
The Dividend Yield of Biogen Pharmachem Industries Ltd is 0.00 %.
What is the ROCE of Biogen Pharmachem Industries Ltd?
The ROCE of Biogen Pharmachem Industries Ltd is 0.39 %.
What is the ROE of Biogen Pharmachem Industries Ltd?
The ROE of Biogen Pharmachem Industries Ltd is 0.39 %.
What is the Face Value of Biogen Pharmachem Industries Ltd?
The Face Value of Biogen Pharmachem Industries Ltd is 1.00.